Highlights Gilead Sciences, Inc. Buenos Aires S.E.

Equities

GILD

ARBCOM4601C4

End-of-day quote Buenos Aires S.E. Other stock markets 23:00:00 30/06/2024 BST			5-day change	1st Jan Change
24,177 ^ARS	+4.13%		+3.76%	+22.29%

07-01	HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	MT
07-01	HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	07-01	CI
Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia	06-27	CI
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer	06-25	CI
Top Premarket Gainers	06-21	MT
Wall Street futures edge lower ahead of business survey data	06-21	RE
Equity Markets Close Mixed as Investors Weigh Economic Data	06-20	MT
Equity Markets Close Mixed After Macro Data	06-20	MT
Health Care Stocks Rise Behind Gilead -- Health Care Roundup	06-20	DJ
US Equities Markets Close Mixed Thursday as Markets Parse Latest Economic Data	06-20	MT
Sector Update: Health Care Stocks Higher Late Afternoon	06-20	MT
Sector Update: Health Care Stocks Mixed Thursday Afternoon	06-20	MT
Sliding Technology Stocks Push S&P 500, Nasdaq Composite Lower	06-20	MT
Sector Update: Health Care	06-20	MT
Gilead Sciences' Twice-Yearly Shot Prevents 100% of HIV Cases in Trial, Shares Jump	06-20	MT
Gilead Sciences' Lenacapavir Shows 100% Efficacy, Superiority to Truvada For HIV Prevention	06-20	MT
Gilead Sciences HIV Prevention Treatment Shows 100% Effectiveness in Phase 3 Trial	06-20	DJ
Gilead's long-acting HIV drug superior to daily pill Truvada in study	06-20	RE
Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial	06-20	CI
Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup	06-14	DJ
EU regulator mandates label updates on CAR-T cancer therapies	06-14	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Gilead Sciences, Inc. Buenos Aires S.E.

Equities

GILD

ARBCOM4601C4

Highlights

Filters